Effect of ketoconazole on the pharmacokinetics of rosiglitazone in healthy subjects

British Journal of Clinical Pharmacology

Volumn 58, Issue 4, 2004, Pages 397-402

  Park, Ji Young ^a   Kim, Kyoung Ah ^b   Shin, Jae Gook ^b   Lee, Ki Young ^b  

^a Gachon University College of Medicine   (South Korea)

^b NONE

Author keywords

CYP2C8; Drug interaction; Ketoconazole; Pharmacokinetics; Rosiglitazone

Indexed keywords

CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; GEMFIBROZIL; KETOCONAZOLE; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE;

ADULT; ANASARCA; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONCENTRATION RESPONSE; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG DISPOSITION; DRUG EFFICACY; ENZYME INHIBITION; GLUCOSE METABOLISM; HUMAN; HUMAN EXPERIMENT; KOREA; LIVER TOXICITY; LUNG EDEMA; MALE; MYCOSIS; NORMAL HUMAN; OPEN STUDY; PERIPHERAL EDEMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE;

ADULT; ANTIFUNGAL AGENTS; CROSS-OVER STUDIES; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; KETOCONAZOLE; MALE; THIAZOLIDINEDIONES;

EID: 4744348757     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2004.02161.x     Document Type: Article

References (34)

1. Malinowski JM, Bolesta S. Rosiglitazone in the treatment of type 2 diabetes mellitus: a critical review. Clin Ther 2000; 22: 1151-68.
2. Balfour JA, Plosker GL. Rosiglitazone. Drugs 1999; 57: 921-30.
3. Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma). J Biol Chem 1995; 270: 12953-6.
4. Cox PJ, Ryan DA, Hollis FJ et al. Absorption, disposition, and metabolism of rosiglitazone, a potent thiazolidinedione insulin sensitizer, in humans. Drug Metab Dispos 2000; 28: 772-80.
5. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999; 48: 424-32.
6. Bolton GC, Keogh JP, East PD, Hollis FJ, Shore AD. The fate of a thiazolidinedione antidiabetic agent in rat and dog. Xenobiotica 1996; 26: 627-36.
7. Daneshmend TK, Warnock DW. Clinical pharmacokinetics of ketoconazole. Clin Pharmacokinet 1988; 14: 13-34.
8. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915-28.
9. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. Clin Pharmacokinet 2000; 38: 111-80.
10. Reunanen A, Kangas T, Martikainen J, Klaukka T. Nationwide survey of comorbidity, use, and costs of all medications in Finnish diabetic individuals. Diabetes Care 2000; 23: 1265-71.
11. Bun SS, Ciccolini J, Bun H, Aubert C, Catalin J. Drug interactions of paclitaxel metabolism in human liver microsomes. J Chemother 2003; 15: 266-74.
12. Ong CE, Coulter S, Birkett DJ, Bhasker CR, Miners JO. The xenobiotic inhibitor profile of cytochrome P4502C8. Br J Clin Pharmacol 2000; 50: 573-80.
13. Park JY, Kim KA, Kang MH, Shin JG. Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin Pharmacol Ther 2004; 75: 157-62.
14. Miller AK, DiCicco RA, Freed MI. The effect of ranitidine on the pharmacokinetics of rosiglitazone in healthy adult male volunteers. Clin Ther 2002; 24: 1062-71.
15. Miller AK, Inglis AM, Culkin KT, Jorkasky DK, Freed MI. The effect of acarbose on the pharmacokinetics of rosiglitazone. Eur J Clin Pharmacol 2001; 57: 105-9.
16. Rao MN, Mullangi R, Katneni K et al. Lack of effect of sucralfate on the absorption and pharmacokinetics of rosiglitazone. J Clin Pharmacol 2002; 42: 670-5.
17. Niemi M, Backman JT, Granfors M, Laitila J, Neuvonen M, Neuvonen PJ. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone. Diabetologia 2003; 46: 1319-23.
18. Krishnaiah YS, Satyanarayana S, Visweswaram D. Interaction between tolbutamide and ketoconazole in healthy subjects. Br J Clin Pharmacol 1994; 37: 205-7.
19. Sonnichsen DS, Liu Q, Schuetz EG, Schuetz JD, Pappo A, Relling MV. Variability in human cytochrome P450 paclitaxel metabolism. J Pharmacol Exp Ther 1995; 275: 566-75.
20. Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 1999; 58: 1201-8.
21. Ohyama K, Nakajima M, Nakamura S, Shimada N, Yamazaki H, Yokoi T. A significant role of human cytochrome P450 2C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000; 28: 1303-10.
22. Li XQ, Bjorkman A, Andersson TB, Ridderstrom M, Masimirembwa CM. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002; 300: 399-407.
23. Yoon YR, Shon JH, Kim MK et al. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population. Br J Clin Pharmacol 2001; 51: 277-80.
24. Cho J, Suh Y, Lee J et al. Identification of polymorphism in human CYP2C8 gene by two-dimensional gel scanning in healthy Koreans. Clin Pharmacol Ther 2003; 73: P41.
25. Avandia® (GlaxoSmithKline). PDR Electronic Library™ 2003. Montvale, NJ: Thomson Medical Economics, 2003: 1.
26. Watanabe I, Tomita A, Shimizu M et al. A study to survey susceptible genetic factors responsible for troglitazone-associated hepatotoxicity in Japanese patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2003; 73: 435-55.
27. Otto C, Lehrke M, Coke B. Novel insulin sensitizer: pharmacogenomic aspects. Pharmacogenomics 2002; 3: 99-116.
28. Kermani A, Garg A. Thiazolidinedione-associated congestive heart failure and pulmonary edema. Mayo Clin Proc 2003; 78: 1088-91.
29. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002; 22: 924-9.
30. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone. Ann Pharmacother 2001; 35: 123-4.
31. Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003; 46: 288-90.
32. Eckland DA, Danhof M. Clinical pharmacokinetics of pioglitazone. Exp Clin Endocrinol 2001; 108: S234-S242.
33. Albengres E, Le Louet H, Tillement JP. Systemic antifungal agents. Drug interactions of clinical significance. Drug Saf 1998; 18: 83-97.
34. Lomaestro BM, Piatek MA. Update on drug interactions with azole antifungal agents. Ann Pharmacother 1998; 32: 915-28.